ClinicalTrials.gg
CompletedNCT07271940Updated Nov 16, 2026

Full Plate Living Nutrition Education Program

An interventional study of Full Plate Living Nutrition Education Program in Diabetes Mellitus, Pre Diabetes and Obesity, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetes Mellitus by University of Wisconsin, Madison — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus · University of Wisconsin, Madison.

Enrollment
5th of 12
42 · median 32
Started
2026
with 2 others
No phase
10 of 18
3 open now
Registered
17th of 18
by date

Among the 18 studies in Diabetes Mellitus by University of Wisconsin, Madison, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 17th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

3 of the 18 studies in Diabetes Mellitus by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetes Mellitus by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

The purpose of the research is to evaluate the acceptability and feasibility of implementing a 8-session nutritional education program in a general internal medicine clinic. This program emphasizes a fiber-rich, whole foods diet consisting of fruits, vegetables, legumes, whole grains, nuts and seeds. Such interventions can improve diabetes management and lead to weight loss. 48 participants will be enrolled and on study for approximately 5 months.

03

Conditions studied

  • Diabetes Mellitus
  • Pre Diabetes
  • Obesity

Keywords

  • fiber
  • nutrition
04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-diabetes or diabetes
  • (BMI) 30-42
  • UW Health Primary Care Physician

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Active cancer (treatment within one year or planning on having treatment)
  • Eating Disorder (SDE Screening 2+)
  • Chronic Kidney Disease (CKD) (Stage 4 or 5)
  • Patient Health Questionnaire-9 (PHQ9) indicating severe depression (greater than 15)
  • No PHQ9 and PHQ2 greater than 2
  • General Anxiety Disorder-7 (GAD7) indicating severe anxiety (greater than 15)
  • No GAD 7 and GAD2 greater than 2
  • Inflammatory bowel disease (IBD)
  • Irritable bowel syndrome (IBS)
  • Readiness to Change less than 7
  • Confidence to Change less than 7
  • Lack of transportation
  • Non-English Speaking
  • No control over food environment
  • No access to laptop, desktop computer, or tablet
  • No email or text message access
  • Unwilling to participate in a shared medical visit
  • Unable to attend one of the four concurrent shared medical visit session cohorts
  • For those on insulin, no access to finger-prick blood glucose meter or continuous glucose monitor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Full Plate Living Nutrition Education Program

    Other: Full Plate Living Nutrition Education Program

Interventions

  • OtherFull Plate Living Nutrition Education Program

    Participants will attend 8 sessions over 8 weeks. Participants will learn about the importance of fiber and how to add fiber to their diet.

06

What researchers measure

Primary outcomes

  1. Participant Weight

    Time frame: retrospectively from 2 years prior to enrollment and up to 20 weeks on study (3 month follow up)

Secondary outcomes

  1. Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24)

    Dietary fiber (grams per day) will be measured using the Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24) which has been validated for measuring fiber intake in adults. The ASA24 is a free, web-based tool. Participants will complete the ASA24 online two times prior to the first session, 2 times prior to the last session, and 2 times 3 months after the last session.

    Time frame: baseline, 8 weeks, 20 weeks (3 month follow up)

  2. Participant Quality of Life measured by the SF-12 score

    Possible scores range from 0-100 with higher scores indicating better quality of life.

    Time frame: baseline, 8 weeks, 20 weeks (3 month follow up)

  3. Acceptability: Percent of Participants who found the intervention acceptable

    A subset of participants will be invited to complete an individual interview after the last session. The aim is to schedule 8-12 participants for interviews including both participants who completed all the sessions and those stopped attending sessions. Data will be derived from these qualitative semi-structured interviews.

    Time frame: Participant surveyed at the end of last session, approximately 8 weeks

  4. Feasibility: Participant Retention Rate

    Feasibility will in part be measured by participant retention rate, the number of participants who complete each time point of data collection over the number of participants enrolled.

    Time frame: baseline, 8 weeks, 20 weeks (3 month follow up)

  5. Feasibility: Participation Rate

    Feasibility will in part be measured by participation rate, the number of participants enrolled over the target enrollment.

    Time frame: Through enrollment (up to 3 months)

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Sep 2026, 7 months.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 7 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jan 2027 → Sep 2026 and completion Jan 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 9, 2025
StartActual
Jan 12, 2026
Primary completionActual
Sep 1, 2026was Jan 2027
CompletionActual
Sep 1, 2026was Jan 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Jan 2027→Sep 1, 2026 (actual)
Nov 16, 2026
Study completion
Jan 2027→Sep 1, 2026 (actual)
Nov 16, 2026
Documents
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Jan 2027→Sep 1, 2026 (now actual)
    Study completion Jan 2027→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07271940
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Jan 12, 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Nov 16, 2026

Study contacts

Katie Miller, MD
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion